Clinical Trial Detail

NCT ID NCT02672475
Title Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Vanderbilt-Ingram Cancer Center
Indications

triple-receptor negative breast cancer

Therapies

Galunisertib + Paclitaxel

Age Groups: adult

No variant requirements are available.